Leukemia patients continue promising drug in Long-Term safety check

NCT ID NCT04877522

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 23 times

Summary

This study is for people with chronic myeloid leukemia who are already taking the drug asciminib and benefiting from it. The goal is to monitor long-term safety and side effects while they continue treatment. About 347 participants will be followed, and doctors will also check if patients still benefit from the drug over time.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-••••

Locations

Memorial Sloan Kettering
RECRUITING

New York, New York, 10017, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
Michigan Med University of Michigan
RECRUITING

Ann Arbor, Michigan, 48109 5271, United States

Contact Email: •••••@•••••

Contact
Novartis Investigative Site
RECRUITING

CABA, Buenos Aires, C1221ADC, Argentina
Novartis Investigative Site
RECRUITING

Capital Federal, C1114AAN, Argentina
Novartis Investigative Site
RECRUITING

Graz, 8036, Austria
Novartis Investigative Site
RECRUITING

Vienna, 1140, Austria
Novartis Investigative Site
COMPLETED

Rio de Janeiro, Rio de Janeiro, 20211-030, Brazil
Novartis Investigative Site
COMPLETED

São Paulo, São Paulo, 05403 000, Brazil
Novartis Investigative Site
COMPLETED

São Paulo, São Paulo, 08270-070, Brazil
Novartis Investigative Site
RECRUITING

Varna, 9000, Bulgaria
Novartis Investigative Site
RECRUITING

Montreal, Quebec, H1T 2M4, Canada
Novartis Investigative Site
RECRUITING

Chongqing, Chongqing Municipality, 400010, China
Novartis Investigative Site
RECRUITING

Guangzhou, Guangdong, 510515, China
Novartis Investigative Site
RECRUITING

Zhengzhou, Henan, 450008, China
Novartis Investigative Site
RECRUITING

Wuhan, Hubei, 430022, China
Novartis Investigative Site
RECRUITING

Changchun, Jilin, 130021, China
Novartis Investigative Site
RECRUITING

Xian, Shanxi, 710004, China
Novartis Investigative Site
COMPLETED

Chengdu, Sichuan, 610041, China
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Beijing, 100044, China
Novartis Investigative Site
RECRUITING

Beijing, 100730, China
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Shanghai, 200025, China
Novartis Investigative Site
RECRUITING

Shenyang, 110004, China
Novartis Investigative Site
RECRUITING

Tianjin, 300020, China
Novartis Investigative Site
RECRUITING

Ostrava, Poruba, 708 52, Czechia
Novartis Investigative Site
RECRUITING

Brno, 625 00, Czechia
Novartis Investigative Site
COMPLETED

Copenhagen, DK-2100, Denmark
Novartis Investigative Site
RECRUITING

Bordeaux, 33076, France
Novartis Investigative Site
RECRUITING

Lyon, 69373, France
Novartis Investigative Site
RECRUITING

Marseille, 13273, France
Novartis Investigative Site
RECRUITING

Nantes, 44093, France
Novartis Investigative Site
RECRUITING

Paris, 75475, France
Novartis Investigative Site
RECRUITING

Vandœuvre-lès-Nancy, 54511, France
Novartis Investigative Site
RECRUITING

Frankfurt am Main, Hesse, 60590, Germany
Novartis Investigative Site
RECRUITING

Jena, Thuringia, 07740, Germany
Novartis Investigative Site
RECRUITING

Berlin, 13353, Germany
Novartis Investigative Site
RECRUITING

Kiel, 24116, Germany
Novartis Investigative Site
RECRUITING

Milan, MI, 20162, Italy
Novartis Investigative Site
RECRUITING

Roma, RM, 00161, Italy
Novartis Investigative Site
COMPLETED

Naples, 80131, Italy
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Kobe, 650-0017, Japan
Novartis Investigative Site
COMPLETED

Beirut, 113-0236, Lebanon
Novartis Investigative Site
RECRUITING

George Town, Pulau Pinang, 10450, Malaysia
Novartis Investigative Site
RECRUITING

Johor Bahru, 80100, Malaysia
Novartis Investigative Site
RECRUITING

Kuala Selangor, 68000, Malaysia
Novartis Investigative Site
RECRUITING

Monterrey, Nuevo León, 64460, Mexico
Novartis Investigative Site
RECRUITING

Khoudh, 123, Oman
Novartis Investigative Site
RECRUITING

Katowice, 40-519, Poland
Novartis Investigative Site
COMPLETED

Krakow, 30-688, Poland
Novartis Investigative Site
RECRUITING

Warsaw, 00-791, Poland
Novartis Investigative Site
COMPLETED

Wroclaw, 50 367, Poland
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Lisbon, 1099-023, Portugal
Novartis Investigative Site
RECRUITING

Porto, 4200-072, Portugal
Novartis Investigative Site
COMPLETED

Timișoara, 300079, Romania
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Moscow, 125167, Russia
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Moscow, 125284, Russia
Novartis Investigative Site
RECRUITING

Saint Petersburg, 191024, Russia
Novartis Investigative Site
RECRUITING

Saint Petersburg, 197341, Russia
Novartis Investigative Site
COMPLETED

Riyadh, 11211, Saudi Arabia
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Singapore, 169608, Singapore
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Uijeongbu-si, Gyeonggi-do, 11759, South Korea
Novartis Investigative Site
COMPLETED

Busan, 49201, South Korea
Novartis Investigative Site
COMPLETED

Jeollanam, 519763, South Korea
Novartis Investigative Site
RECRUITING

Seoul, 03080, South Korea
Novartis Investigative Site
RECRUITING

Santiago Compostela, A Coruna, 15706, Spain
Novartis Investigative Site
RECRUITING

Badalona, Barcelona, 08916, Spain
Novartis Investigative Site
RECRUITING

L'Hospitalet de Llobregat, Barcelona, 08907, Spain
Novartis Investigative Site
RECRUITING

Bilbao, Bizkaia, 48013, Spain
Novartis Investigative Site
RECRUITING

Santa Cruz, Santa Cruz De Tenerife, 38009, Spain
Novartis Investigative Site
RECRUITING

Barcelona, 08035, Spain
Novartis Investigative Site
COMPLETED

Barcelona, 08036, Spain
Novartis Investigative Site
RECRUITING

Madrid, 28006, Spain
Novartis Investigative Site
COMPLETED

Madrid, 28034, Spain
Novartis Investigative Site
RECRUITING

Madrid, 28041, Spain
Novartis Investigative Site
RECRUITING

Seville, 41009, Spain
Novartis Investigative Site
RECRUITING

Valencia, 46026, Spain
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Taoyuan, 33305, Taiwan
Novartis Investigative Site
RECRUITING

Samsun, Atakum, 55200, Turkey (Türkiye)
Novartis Investigative Site
RECRUITING

London, W12 0HS, United Kingdom
Novartis Investigative Site
RECRUITING

Oxford, OX3 7LE, United Kingdom
Novartis Investigative Site
RECRUITING

Hanoi, 100000, Vietnam
Novartis Investigative Site
RECRUITING

Ho Chi Minh City, 70000, Vietnam
Oregon Health Sciences University
ACTIVE_NOT_RECRUITING

Portland, Oregon, 97239, United States
Texas Oncology
RECRUITING

Dallas, Texas, 75251, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Uni Of TX MD Anderson Cancer Cntr
RECRUITING

Houston, Texas, 77030, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

CHRONIC MYELOGENOUS LEUKEMIA LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE